Antidiabetic medication Flashcards

1
Q

when will metformin (biguanide) only work?

A

if some Bcells work in islet of langherhans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

how does metformin (biguanide) work

A

decreases glucogensis and increases peripheral utilisation of glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

s/e of metformin (biguanide)

A

-lactic acidosis - avoid if EGFR <30
-GI s/e = high dose slowly or give MR
-can lower vit B12
-stop if pt = AKI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

sulphonylureas MoA

A

Augments insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

examples of short acting sulphonylureas

A

gliclazide
tolbutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

examples of long-acting sulphonylurea

A

glibericlamide
glimepiride

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

why should you avoid long-acting sulphonylurea in elderly?

A

it is assoc with prolonged and fatal cases of hypoglyc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

s/e sulphonylurea

A

high risk of hypoglyc
tx in hosp (target = 7.0% x 6.5%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

when should you avoid sulphonylureas?

A

-avoid in acute porphyria
-avoid in hepatic + renal failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MoA of pioglitazone

A

decreases peripheral insulin resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

when should you avoid pioglitazone

A

in pts with history of HF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

high risk of?

pioglitazone S/E

A

-high risk of bladder cancer
-high risk of bone factors
-high risk of liver toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

pioglitazone s/e

what should you review with bladder cancer and when

A

safety and efficacy after 3-6MT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

s/e pioglitazone

when should you not tx pt who develop bladder cancer

A

if they have an inadequate response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

pioglitazone s/e

what signs should you report if bladder cancer is suspected

A

haematuria
dysuria
urinary urgency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

pioglitazone S/E

What sings of liver toxicity should you report?

A

nausea, vomiting, abdominal pain, fatigue + dark urine

17
Q

examples of Dipeptidyl peptidase 4- inhibitors (DPP-4i)

A

vildagliptin
aloglipitin
linagliptin
saxagliptin
sitagliptin

18
Q

vildagliptin, aloglipitin, linagliptin, saxagliptin, sitagliptin

MoA of DPP-4i

A

inhibits DPP-4i to inc insulin secretion and lower glucagon secretion

19
Q

vildagliptin, aloglipitin, linagliptin, saxagliptin, sitagliptin

what can DPP-4i cause and the symptoms

A

pancreatitis
-x treat if symptoms of acute pancreatitis develop
-persistent, severe, abdominal pain

20
Q

vildagliptin, aloglipitin, linagliptin, saxagliptin, sitagliptin

which DPP-4i is most hepatotoxic?

A

vildagliptin

21
Q

Dapagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin

MoA of sodium glucose co-transporter 2 inhibitors (SGLT-2i)

A

inhibit sodium glucose co-transporter 2 in renal proximal convulated tubule = more urine = less blood glucose level

22
Q

Dapagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin

MHRA warnings with SGLT-2i

A

-life-threatening + cases of diabetic ketoacidosis
-if tx interrupted for surgery/illness then monitor ketones
-Fournier’s gangrene (necrotising fasciitis of genitalia or perineum)
-canagliflozin only: risk of lower-limb amputation (toes)

23
Q

Dapagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin

monitoring for SGLT-2i

A

renal function

24
Q

Dapagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin

tx if volume depletion occurs with SGLT-2i

A

volume depletion correct hypovolaemia before starting tx

25
Q

dulaglutide, exenatide, liraglutide,

lixesenatide

MoA of GLP-1 agonist

A

inc insulin secretion
supress glucagon secretion slows gastric emptying

26
Q

dulaglutide, exenatide, liraglutide, lixesenatide

MHRA warning of GLP-1 agonist

A

risk of diabetic ketoacidosis when concimitant insulin was dec rapidly

27
Q

dulaglutide, exenatide, liraglutide, lixesenatide

GLP-1 agonist s/e

A

-acute pancreatitis - pt warned of severe abdominal pain
-dehydration risk due to GI s/e avoid fluid deplation

28
Q

examples of GLP-1 agonist

A

dulaglutide
exenatide
liraglutide
lixesenatide

29
Q

MoA of acarbose

A

delays digestion + absorption of starch and sucrose

30
Q

acarbose s/e

A

-high risk of GI s/e may decrease dose

31
Q

examples of meglitides

A

nateglinide
repaglinide

32
Q

nateglinide

repaglinide

MoA of meglitides

A

stimulatess insulin secretion

33
Q

nateglinide, repaglinide

s/e and tx of meglitides

A

stress exposure = tx with interruption + replacement with insulin to maintain glycaemic control

34
Q

Which antidiabetics increase weight?

A

PIS
sulphonylureas
insulin
pioglitazone

35
Q

Which antidiabetics has neutral effect on weight?

A

DPP-4i
metformin

36
Q

Which antidiabetics lowers weight?

A

GLP-1 + SGLT-2i